Advanced search
Publication Cover
OncoImmunology Volume 5, 2016 - Issue 10
Submit an article Journal homepage
3,293
Views
89
CrossRef citations to date
0
Altmetric
Original Research

Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia

Emily M. McWilliamsBiomedical Sciences Graduate Program, The Ohio State University, Columbus, OH, USA;Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
,
Jennifer M. MeleDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
,
Carolyn CheneyDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
,
Elizabeth A. TimmermanDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
,
Faraz FiazuddinDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
,
Ethan J. StrattanDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
,
Xiaokui MoCenter for Biostatistics, The Ohio State University, Columbus, OH, USA
,
John C. ByrdDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
,
Natarajan MuthusamyDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
&
Farrukh T. AwanDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USACorrespondence[email protected]
 show all
Article: e1226720 | Received 18 Jul 2016, Accepted 16 Aug 2016, Published online: 11 Oct 2016

Citations (89)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Adeline Raynaud, Klervi Desrumeaux, Laurent Vidard, Elise Termine, Daniel Baty, Patrick Chames, Emmanuelle Vigne & Brigitte Kerfelec. (2021) Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response. OncoImmunology 10:1.
Read now
Alexander W. MacFarlane$suffix/text()$suffix/text(), Mowafaq Jillab, Mitchell R. Smith, R. Katherine Alpaugh, Marion E. Cole, Samuel Litwin, Michael M. Millenson, Tahseen Al-Saleem, Adam D. Cohen & Kerry S. Campbell. (2017) NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors. OncoImmunology 6:7.
Read now

Articles from other publishers (87)

Jack G. Fisher, Amber D. P. Doyle, Lara V. Graham, Shreyanshi Sonar, Ben Sale, Isla Henderson, Luis Del Rio, Peter W. M. Johnson, Yosef Landesman, Mark S. Cragg, Francesco Forconi, Christopher J. Walker, Salim. I. Khakoo & Matthew D. Blunt. (2023) XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression. Leukemia.
Crossref
Luiz Ricardo Soldi, Victor Luigi Costa Silva, Diogo Henrique Rabelo, Isadora Akemi Uehara & Marcelo José Barbosa Silva. (2023) Reactivation of natural killer cells with monoclonal antibodies in the microenvironment of malignant neoplasms. Journal of Cancer Research and Clinical Oncology 149:9, pages 6661-6673.
Crossref
Christian Sordo-Bahamonde, Seila Lorenzo-Herrero, Alejandra Martínez-Pérez, Ana P. Gonzalez-Rodriguez, Ángel R. Payer, Esther González-García, Candelaria Aguilar-García, Sara González-Rodríguez, Alejandro López-Soto, Alejandra García-Torre & Segundo Gonzalez. (2023) BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia. Cancer Immunology, Immunotherapy 72:7, pages 2529-2539.
Crossref
Xiaohu Zheng, Zhuanghao Hou, Yeben Qian, Yongwei Zhang, Quanwei Cui, Xuben Wang, Yiqing Shen, Zhenbang Liu, Yonggang Zhou, Binqing Fu, Rui Sun, Zhigang Tian, Guangming Huang & Haiming Wei. (2023) Tumors evade immune cytotoxicity by altering the surface topology of NK cells. Nature Immunology 24:5, pages 802-813.
Crossref
Tomonori Iyoda, Satoru Yamasaki, Shogo Ueda, Kanako Shimizu & Shin-ichiro Fujii. (2023) Natural Killer T and Natural Killer Cell-Based Immunotherapy Strategies Targeting Cancer. Biomolecules 13:2, pages 348.
Crossref
Wern Lynn Ng, Stephen M. Ansell & Patrizia Mondello. (2022) Insights into the tumor microenvironment of B cell lymphoma. Journal of Experimental & Clinical Cancer Research 41:1.
Crossref
Chenyu Lin, Mitchell E. Horwitz & Lindsay A. M. Rein. (2022) Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond. International Journal of Molecular Sciences 24:1, pages 204.
Crossref
Junqiang Lv, Hao Sun, Lixin Gong, Xiaojing Wei, Yi He, Zhen Yu, Lanting Liu, Shuhua Yi, Weiwei Sui, Yan Xu, Shuhui Deng, Gang An, Zhi Yao, Lugui Qiu & Mu Hao. (2022) Aberrant metabolic processes promote the immunosuppressive microenvironment in multiple myeloma. Frontiers in Immunology 13.
Crossref
Max Yano, John C. Byrd & Natarajan Muthusamy. (2022) Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential. Cancers 14:23, pages 5787.
Crossref
Jack Fisher, Amber Doyle, Lara Graham, Salim Khakoo & Matthew Blunt. (2022) Disruption of the NKG2A:HLA-E Immune Checkpoint Axis to Enhance NK Cell Activation against Cancer. Vaccines 10:12, pages 1993.
Crossref
Enrico Munari, Linda Quatrini, Cecilia Ciancaglini, Albino Eccher, Giuseppe Bogina, Lorenzo Moretta & Francesca Romana Mariotti. (2022) Immunotherapy targeting inhibitory checkpoints: The role of NK and other innate lymphoid cells. Seminars in Immunology 61-64, pages 101660.
Crossref
Max Yano, Chia Sharpe, J. Rachel Lance, Janani Ravikrishnan, Kevan Zapolnik, Xiaokui Mo, Jennifer A. Woyach, Deepa Sampath, Adam S. Kittai, Sumithira Vasu, Seema Bhat, Kerry A. Rogers, Dean A. Lee, Natarajan Muthusamy & John C. Byrd. (2022) Evaluation of allogeneic and autologous membrane-bound IL-21–expanded NK cells for chronic lymphocytic leukemia therapy. Blood Advances 6:20, pages 5641-5654.
Crossref
Xiaotong Wang, Huabao Xiong & Zhaochen Ning. (2022) Implications of NKG2A in immunity and immune-mediated diseases. Frontiers in Immunology 13.
Crossref
Antonio Valeri, Almudena García-Ortiz, Eva Castellano, Laura Córdoba, Elena Maroto-Martín, Jessica Encinas, Alejandra Leivas, Paula Río & Joaquín Martínez-López. (2022) Overcoming tumor resistance mechanisms in CAR-NK cell therapy. Frontiers in Immunology 13.
Crossref
Junfeng Chu, Fengcai Gao, Meimei Yan, Shuang Zhao, Zheng Yan, Bian Shi & Yanyan Liu. (2022) Natural killer cells: a promising immunotherapy for cancer. Journal of Translational Medicine 20:1.
Crossref
Hüseyin KAYA, Seda KUŞOĞLU GÜLTEKİN & Belkis ATASEVER ARSLAN. (2022) Doğal Öldürücü Hücre Aktivitesinde İmmunomodulatör Etki Gösteren MoleküllerMolecules That Show Immunomodulator Effect on Natural Killer Cell Activity. Black Sea Journal of Health Science 5:2, pages 312-317.
Crossref
Veronica Ramos-Mejia, Jose Arellano-Galindo, Juan Manuel Mejía-Arangure & Mario Ernesto Cruz-Munoz. (2022) A NK Cell Odyssey: From Bench to Therapeutics Against Hematological Malignancies. Frontiers in Immunology 13.
Crossref
Wanze Zhang, Zhenghua Zhao & Fan Li. (2022) Natural killer cell dysfunction in cancer and new strategies to utilize NK cell potential for cancer immunotherapy. Molecular Immunology 144, pages 58-70.
Crossref
Arosh S Perera Molligoda Arachchige. (2022) NK cell-based therapies for HIV infection: Investigating current advances and future possibilities. Journal of Leukocyte Biology 111:4, pages 921-931.
Crossref
Siqin Duan & Shuwen Liu. (2022) Targeting NK Cells for HIV-1 Treatment and Reservoir Clearance. Frontiers in Immunology 13.
Crossref
Hajar Alemohammad, Basira Najafzadeh, Zahra Asadzadeh, Amir Baghbanzadeh, Farid Ghorbaninezhad, Arezoo Najafzadeh, Hossein Safarpour, Renato Bernardini, Oronzo Brunetti, Margherita Sonnessa, Rossella Fasano, Nicola Silvestris & Behzad Baradaran. (2022) The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer. Biomedicine & Pharmacotherapy 146, pages 112516.
Crossref
Mojgan Astaneh, Hadiseh Rezazadeh, Hadi Hossein-Nataj, Ramin Shekarriz, Ehsan Zaboli, Mahdi Shabani & Hossein Asgarian-Omran. (2022) Tim-3 and PD-1 blocking cannot restore the functional properties of natural killer cells in early clinical stages of chronic lymphocytic leukemia: An in vitro study. Journal of Cancer Research and Therapeutics 18:3, pages 704.
Crossref
Jack G. Fisher, Christopher J. Walker, Amber DP. Doyle, Peter WM. Johnson, Francesco Forconi, Mark S. Cragg, Yosef Landesman, Salim. I. Khakoo & Matthew D. Blunt. (2021) Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E. Frontiers in Oncology 11.
Crossref
Yingyue Liu, Xiangxiang Zhou & Xin Wang. (2021) Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities. Journal of Hematology & Oncology 14:1.
Crossref
Rodion A. Velichinskii, Maria A. Streltsova, Sofya A. Kust, Alexander M. Sapozhnikov & Elena I. Kovalenko. (2021) The Biological Role and Therapeutic Potential of NK Cells in Hematological and Solid Tumors. International Journal of Molecular Sciences 22:21, pages 11385.
Crossref
Graeme Gardner & Christopher A. Fraker. (2021) Natural Killer Cells as Key Mediators in Type I Diabetes Immunopathology. Frontiers in Immunology 12.
Crossref
Sarah B. Reusing, Angela R. Manser, Stefanie Groeneveld-Krentz, Vera Rebmann, Peter A. Horn, Roland Meisel, Leonid Karawajew, Arndt Borkhardt, Markus Uhrberg & Florian Babor. (2021) HLA-E expression constitutes a novel determinant for ALL disease monitoring following hematopoietic stem cell transplantation. Bone Marrow Transplantation 56:7, pages 1723-1727.
Crossref
Mepur H. Ravindranath & Fatiha E.L. Hilali. 2021. Monoclonal Antibodies. Monoclonal Antibodies.
Paolo Sportoletti, Filomena De Falco, Beatrice Del Papa, Stefano Baldoni, Valerio Guarente, Andrea Marra, Erica Dorillo, Chiara Rompietti, Francesco Maria Adamo, Loredana Ruggeri, Mauro Di Ianni & Emanuela Rosati. (2021) NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications. International Journal of Molecular Sciences 22:13, pages 6665.
Crossref
Nina Miazek-Zapala, Aleksander Slusarczyk, Aleksandra Kusowska, Piotr Zapala, Matylda Kubacz, Magdalena Winiarska & Malgorzata Bobrowicz. (2021) The “Magic Bullet” Is Here? Cell-Based Immunotherapies for Hematological Malignancies in the Twilight of the Chemotherapy Era. Cells 10:6, pages 1511.
Crossref
Raynier Devillier, Anne-Sophie Chrétien, Thomas Pagliardini, Nassim Salem, Didier Blaise & Daniel Olive. (2021) Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy. Journal of Leukocyte Biology 109:6, pages 1071-1088.
Crossref
Hannah Wurzer, Liza Filali, Céline Hoffmann, Max Krecke, Andrea Michela Biolato, Jérôme Mastio, Sigrid De Wilde, Jean Hugues François, Anne Largeot, Guy Berchem, Jérôme Paggetti, Etienne Moussay & Clément Thomas. (2021) Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome In Vitro by Pharmacological Inhibition of Cdc42-Induced Actin Cytoskeleton Remodeling. Frontiers in Immunology 12.
Crossref
Christian Sordo-Bahamonde, Seila Lorenzo-Herrero, Ana P. González-Rodríguez, Ángel R. Payer, Esther González-García, Alejandro López-Soto & Segundo Gonzalez. (2021) LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia. Cancers 13:9, pages 2112.
Crossref
Frederique St-Pierre, Shailender Bhatia & Sunandana Chandra. (2021) Harnessing Natural Killer Cells in Cancer Immunotherapy: A Review of Mechanisms and Novel Therapies. Cancers 13:8, pages 1988.
Crossref
Christian Sordo-Bahamonde, Seila Lorenzo-Herrero, Ana P Gonzalez-Rodriguez, Ángel R. Payer, Esther González-García, Alejandro López-Soto & Segundo Gonzalez. (2021) BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia. Cancers 13:8, pages 1766.
Crossref
Nayoung Kim, Dong-Hee Lee, Woo Seon Choi, Eunbi Yi, HyoJeong Kim, Jung Min Kim, Hyung-Seung Jin & Hun Sik Kim. (2021) Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors. BMB Reports 54:1, pages 44-58.
Crossref
Hantae Jo, Byungsun Cha, Haneul Kim, Sofia Brito, Byeong Mun Kwak, Sung Tae Kim, Bum-Ho Bin & Mi-Gi Lee. (2021) α-Pinene Enhances the Anticancer Activity of Natural Killer Cells via ERK/AKT Pathway. International Journal of Molecular Sciences 22:2, pages 656.
Crossref
Xiao Zhu, Shi Li, Bairui Xu & Hui Luo. (2021) Cancer evolution: A means by which tumors evade treatment. Biomedicine & Pharmacotherapy 133, pages 111016.
Crossref
Cordelia Dunai, Craig P. Collins, Isabel Barao & William J. Murphy. 2021. Successes and Challenges of NK Immunotherapy. Successes and Challenges of NK Immunotherapy 3 31 .
Valentina Griggio, Francesca Perutelli, Chiara Salvetti, Elia Boccellato, Mario Boccadoro, Candida Vitale & Marta Coscia. (2020) Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia. Frontiers in Immunology 11.
Crossref
Helmi Alfarra, Jackson Weir, Stacy Grieve & Tony Reiman. (2020) Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy. Frontiers in Immunology 11.
Crossref
Yuqing Cao, Xiaoyu Wang, Tianqiang Jin, Yu Tian, Chaoliu Dai, Crystal Widarma, Rui Song & Feng Xu. (2020) Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy. Signal Transduction and Targeted Therapy 5:1.
Crossref
Mireia Bachiller, Anthony M. Battram, Lorena Perez-Amill & Beatriz Martín-Antonio. (2020) Natural Killer Cells in Immunotherapy: Are We Nearly There?. Cancers 12:11, pages 3139.
Crossref
Xiaoyan Zhao, Li Cai, Yu Hu & Huafang Wang. (2020) Cord-Blood Natural Killer Cell-Based Immunotherapy for Cancer. Frontiers in Immunology 11.
Crossref
Jiao Wang & Sandro Matosevic. (2020) Functional and metabolic targeting of natural killer cells to solid tumors. Cellular Oncology 43:4, pages 577-600.
Crossref
S. Elizabeth Franks, Benjamin Wolfson & James W. Hodge. (2020) Natural Born Killers: NK Cells in Cancer Therapy. Cancers 12:8, pages 2131.
Crossref
Sachin Kumar Singh Chauhan, Ulrike Koehl & Stephan Kloess. (2020) Harnessing NK Cell Checkpoint-Modulating Immunotherapies. Cancers 12:7, pages 1807.
Crossref
Massimo Giuliani & Alessandro Poggi. (2020) Checkpoint Inhibitors and Engineered Cells: New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies. Cells 9:7, pages 1578.
Crossref
Cai Zhang & Yuxia Liu. (2020) Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy. Frontiers in Immunology 11.
Crossref
Christian Sordo-Bahamonde, Massimo Vitale, Seila Lorenzo-Herrero, Alejandro López-Soto & Segundo Gonzalez. (2020) Mechanisms of Resistance to NK Cell Immunotherapy. Cancers 12:4, pages 893.
Crossref
Aviad Ben-Shmuel, Guy Biber & Mira Barda-Saad. (2020) Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?. Frontiers in Immunology 11.
Crossref
Cai Zhang, Yuan Hu & Chongdeng Shi. (2020) Targeting Natural Killer Cells for Tumor Immunotherapy. Frontiers in Immunology 11.
Crossref
Muhammad Khan, Sumbal Arooj & Hua Wang. (2020) NK Cell-Based Immune Checkpoint Inhibition. Frontiers in Immunology 11.
Crossref
Chaopin Yang, Yue Li, Yaozhang Yang & Zhiyi Chen. (2020) Overview of Strategies to Improve Therapy against Tumors Using Natural Killer Cell. Journal of Immunology Research 2020, pages 1-16.
Crossref
J. Peter R. Pelletier & Faisal Mukhtar. 2020. Immunologic Concepts in Transfusion Medicine. Immunologic Concepts in Transfusion Medicine 251 348 .
Jilin Wang, Teddy Yang & Jie Xu. 2020. Regulation of Cancer Immune Checkpoints. Regulation of Cancer Immune Checkpoints 619 649 .
Paola Minetto, Fabio Guolo, Silvia Pesce, Marco Greppi, Valentina Obino, Elisa Ferretti, Simona Sivori, Carlo Genova, Roberto Massimo Lemoli & Emanuela Marcenaro. (2019) Harnessing NK Cells for Cancer Treatment. Frontiers in Immunology 10.
Crossref
Elisa Zaghi, Michela Calvi, Clara Di Vito & Domenico Mavilio. (2019) Innate Immune Responses in the Outcome of Haploidentical Hematopoietic Stem Cell Transplantation to Cure Hematologic Malignancies. Frontiers in Immunology 10.
Crossref
Haoyu Sun & Cheng Sun. (2019) The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy. Frontiers in Immunology 10.
Crossref
Gonzalez-Rodriguez, Villa-Álvarez, Sordo-Bahamonde, Lorenzo-Herrero & Gonzalez. (2019) NK Cells in the Treatment of Hematological Malignancies. Journal of Clinical Medicine 8:10, pages 1557.
Crossref
Tom Hofland, Eric Eldering, Arnon P. Kater & Sanne H. Tonino. (2019) Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences 20:17, pages 4315.
Crossref
Ziqing Chen, Ying Yang, Lisa L. Liu & Andreas Lundqvist. (2019) Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors. Cancers 11:7, pages 1040.
Crossref
Kiran Kundu, Susmita Ghosh, Rhitajit Sarkar, Avishay Edri, Michael Brusilovsky, Orly Gershoni-Yahalom, Rami Yossef, Avishai Shemesh, Jean-Charles Soria, Vladimir Lazar, Ben-Zion Joshua, Kerry S. Campbell, Moshe Elkabets & Angel Porgador. (2019) Inhibition of the NKp44-PCNA Immune Checkpoint Using a mAb to PCNA. Cancer Immunology Research 7:7, pages 1120-1134.
Crossref
Edo Kon & Itai Benhar. (2019) Immune checkpoint inhibitor combinations: Current efforts and important aspects for success. Drug Resistance Updates 45, pages 13-29.
Crossref
Nayoung Kim, Hyeon Ho Lee, Hyo-Jung Lee, Woo Seon Choi, Jinju Lee & Hun Sik Kim. (2019) Natural killer cells as a promising therapeutic target for cancer immunotherapy. Archives of Pharmacal Research 42:7, pages 591-606.
Crossref
Hyung-Don Kim & Su-Hyung Park. (2019) Immunological and clinical implications of immune checkpoint blockade in human cancer. Archives of Pharmacal Research 42:7, pages 567-581.
Crossref
Daniel R Ram, Cordelia Manickam, Olivier Lucar, Spandan V Shah & R Keith Reeves. (2019) Adaptive NK cell responses in HIV/SIV infections: A roadmap to cell-based therapeutics?. Journal of Leukocyte Biology 105:6, pages 1253-1259.
Crossref
Elisa Zaghi, Michela Calvi, Emanuela Marcenaro, Domenico Mavilio & Clara Di Vito. (2019) Targeting NKG2A to elucidate natural killer cell ontogenesis and to develop novel immune-therapeutic strategies in cancer therapy. Journal of Leukocyte Biology 105:6, pages 1243-1251.
Crossref
Veronika Bachanova, Daniel J. Weisdorf, Tao Wang, Steven G.E. Marsh, Nezih Cereb, Michael D. Haagenson, Stephen R. Spellman, Stephanie J. Lee, Lisbeth A. Guethlein, Peter Parham, Jeffrey S. Miller & Sarah A. Cooley. (2019) Donor Killer Cell Immunoglobulin-Like Receptor Genotype Does Not Improve Graft-versus-Leukemia Responses in Chronic Lymphocytic Leukemia after Unrelated Donor Transplant: A Center for International Blood and Marrow Transplant Research Analysis. Biology of Blood and Marrow Transplantation 25:5, pages 949-954.
Crossref
Mepur H. RavindranathEdward J FilipponeAsokan DevarajanShahab Asgharzadeh. (2019) Enhancing Natural Killer and CD8 + T Cell-Mediated Anticancer Cytotoxicity and Proliferation of CD8 + T Cells with HLA-E Monospecific Monoclonal Antibodies . Monoclonal Antibodies in Immunodiagnosis and Immunotherapy 38:2, pages 38-59.
Crossref
Jeffrey S. MillerLewis L. Lanier. (2019) Natural Killer Cells in Cancer Immunotherapy. Annual Review of Cancer Biology 3:1, pages 77-103.
Crossref
Ming-Chin Chang, Hung-I Cheng, Kate Hsu, Yen-Ning Hsu, Chen-Wei Kao, Yi-Fang Chang, Ken-Hong Lim & Caleb Gonshen Chen. (2019) NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia. Frontiers in Immunology 9.
Crossref
Leila Hadadi, Morteza Hafezi, Ali Akbar  Amirzargar, Ramazan Ali  Sharifian, Saeid Abediankenari & Hossein Asgarian-Omran. (2019) Dysregulated Expression of Tim-3 and NKp30 Receptors on NK Cells of Patients with Chronic Lymphocytic Leukemia. Oncology Research and Treatment 42:4, pages 197-203.
Crossref
Seila Lorenzo-Herrero, Alejandro López-Soto, Christian Sordo-Bahamonde, Ana Gonzalez-Rodriguez, Massimo Vitale & Segundo Gonzalez. (2018) NK Cell-Based Immunotherapy in Cancer Metastasis. Cancers 11:1, pages 29.
Crossref
Niken M. Mahaweni, Femke A. I. Ehlers, Gerard M. J. Bos & Lotte Wieten. (2018) Tuning Natural Killer Cell Anti-multiple Myeloma Reactivity by Targeting Inhibitory Signaling via KIR and NKG2A. Frontiers in Immunology 9.
Crossref
Sara Tognarelli, Sebastian Wirsching, Ivana von Metzler, Bushra Rais, Benedikt Jacobs, Hubert Serve, Peter Bader & Evelyn Ullrich. (2018) Enhancing the Activation and Releasing the Brakes: A Double Hit Strategy to Improve NK Cell Cytotoxicity Against Multiple Myeloma. Frontiers in Immunology 9.
Crossref
Nayoung Kim & Hun Sik Kim. (2018) Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells. Frontiers in Immunology 9.
Crossref
Fang Fang, Weihua Xiao & Zhigang Tian. (2018) Challenges of NK cell-based immunotherapy in the new era. Frontiers of Medicine 12:4, pages 440-450.
Crossref
Niken M. Mahaweni, Femke A. I. Ehlers, Subhashis Sarkar, Johanna W. H. Janssen, Marcel G. J. Tilanus, Gerard M. J. Bos & Lotte Wieten. (2018) NKG2A Expression Is Not per se Detrimental for the Anti-Multiple Myeloma Activity of Activated Natural Killer Cells in an In Vitro System Mimicking the Tumor Microenvironment. Frontiers in Immunology 9.
Crossref
Jillian Rosenberg & Jun Huang. (2018) CD8+ T cells and NK cells: parallel and complementary soldiers of immunotherapy. Current Opinion in Chemical Engineering 19, pages 9-20.
Crossref
Carlos Cuesta-Mateos, Ana Alcaraz-Serna, Beatriz Somovilla-Crespo & Cecilia Muñoz-Calleja. (2018) Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets. Frontiers in Immunology 8.
Crossref
Asma Beldi-Ferchiou & Sophie Caillat-Zucman. (2017) Control of NK Cell Activation by Immune Checkpoint Molecules. International Journal of Molecular Sciences 18:10, pages 2129.
Crossref
Alejandro López-Soto, Segundo Gonzalez, Mark J. Smyth & Lorenzo Galluzzi. (2017) Control of Metastasis by NK Cells. Cancer Cell 32:2, pages 135-154.
Crossref
Jiacheng Bi & Zhigang Tian. (2017) NK Cell Exhaustion. Frontiers in Immunology 8.
Crossref
Maria Carmen Ochoa, Luna Minute, Inmaculada Rodriguez, Saray Garasa, Elisabeth Perez‐Ruiz, Susana Inogés, Ignacio Melero & Pedro Berraondo. (2017) Antibody‐dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells. Immunology & Cell Biology 95:4, pages 347-355.
Crossref
Helena Stabile, Cinzia Fionda, Angela Gismondi & Angela Santoni. (2017) Role of Distinct Natural Killer Cell Subsets in Anticancer Response. Frontiers in Immunology 8.
Crossref
Joachim Koch & Michael Tesar. (2017) Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy. Transfusion Medicine and Hemotherapy 44:5, pages 337-350.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.